Abstract
Purpose
To evaluate the effects of left gastric artery embolization (LGAE) on plasma ghrelin levels, abdominal fat, and body weight in beagles.
Methods
The institutional animal care and use committee approved this study. Fifteen healthy adult beagles (12 male and three female animals) were randomly divided into three experimental groups: LGAE was proceeded with mixed emulsion of bleomycin A5 hydrochloride and lipiodol (group A), and polyvinyl alcohol particles (group B). Transcatheter saline injections in the left gastric artery were performed as a control. Weight and fasting plasma ghrelin levels were obtained at baseline and at weekly intervals for 8 weeks after the procedure in all animals. All animals were scanned and measured by multidetector computed tomography at baseline and at week 8 for evaluation of abdominal fat.
Results
In LGAE-treated animals, plasma ghrelin and body weight significantly decreased compared to control animals (group A: P = 0.007 and P = 0.000; group B: P = 0.004 and P = 0.000, respectively). Subcutaneous fat size was also significantly reduced (P = 0.011 and P = 0.027 for groups A and B, respectively). The decreasing percentage in ghrelin levels at week 6 (peak of recovery) of LGAE-treated animals were negatively correlated with the size of area supplied by left gastric artery (r = −0.693, P = 0.026).
Conclusion
LGAE could suppress the plasma concentration of ghrelin, which results in subcutaneous fat size reduction and weight loss. Compensatory ghrelin production might occur in the remnant gastric fundus after LGAE.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kojima M, Hosoda H, Date Y et al (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660
Lee HM, Wang G, Englander EW et al (2002) Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 143:185–190
Kojima M, Kangawa K (2005) Ghrelin: structure and function. Physiol Rev 85:495–522
Date Y, Kojima M, Hosoda H et al (2000) Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255–4261
Gnanapavan S, Kola B, Bustin SA et al (2002) The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87:2988–2991
Sakata I, Nakamura K, Yamazaki M et al (2002) Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides 23:531–536
Inui A, Asakawa A, Bowers CY et al (2004) Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J 18:439–456
Arepally A, Barnett BP, Patel TT et al (2008) Catheter-directed gastric artery chemical embolization suppresses systemic ghrelin levels in porcine model. Radiology 249:127–133
Yoshizumi T, Nakamura T, Yamane M et al (1999) Abdominal fat: standardized technique for measurement at CT. Radiology 211:283–286
Bult MJF, Dalen T, Muller AF (2008) Surgical treatment of obesity. Eur J Endocrinol 158:135–145
Fabricatore AN, Wadden TA (2003) Treatment of obesity: an overview. Clin Diabetes 21:67–72
Arepally A, Barnett BP, Montgomery E et al (2007) Catheter-directed gastric artery chemical embolization for modulation of systemic ghrelin levels in a porcine model: initial experience. Radiology 244:138–143
Cummings DE, Shannon MH (2003) Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 138:389–396
Kamegai J, Tamura H, Shimizu T et al (2001) Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and agouti-related protein mRNA levels and body weight in rats. Diabetes 50:2438–2443
Nakazato M, Murakami N, Date Y et al (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194–198
Shintani M, Ogawa Y, Ebihara K et al (2001) Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50:227–232
Tschop M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407:908–913
Wren AM, Seal LJ, Cohen MA et al (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992
Wren AM, Small CJ, Abbott CR et al (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50:2540–2547
Ariyasu H, Takaya K, Tagami T et al (2001) Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 86:4753–4758
Chen Y, Li YH, Zhu QH et al (2008) Fluoroscopic intralesional injection with pingyangmycin lipiodol emulsion for the treatment of orbital venous malformations. AJR Am J Roentgenol 190:966–971
Jeon TY, Lee S, Kim HH et al (2004) Changes in plasma ghrelin concentration immediately after gastrectomy in patients with early gastric cancer. J Clin Endocrinol Metab 89:5392–5396
Acknowledgment
This study was supported by the Natural Science Foundation of China (81060122).
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bawudun, D., Xing, Y., Liu, WY. et al. Ghrelin Suppression and Fat Loss after Left Gastric Artery Embolization in Canine Model. Cardiovasc Intervent Radiol 35, 1460–1466 (2012). https://doi.org/10.1007/s00270-012-0362-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-012-0362-8